NEW UK LIMITED LIST DETAILS ANNOUNCED

25 October 1993

The planned, new UK extension of the National Health Service Limited List of prescribable products to several additional categories of medicines has now been finalized with respect to analgesics, indigestion remedies, vitamins, topical antirheumatics and "borderline" substances. But thus far, the UK Department of Health has made no mention of the two most contentious categories to be de-listed: contraceptives and hormone replacement products, and dermatological preparations.

An announcement from the Ministry notes that 62 medicines - mainly topical antirheumatic preparations - together with 550 foods, toiletries, pesticides and nicotine replacement patches, will no longer be available on prescription from family doctors. Regulations were laid before Parliament on October 11, and these will come into force on November 1.

Parliamentary Secretary for Health Tom Sackville said that the NHS "should not be paying for items which have no therapeutic or clinical value," noting that items such as mineral water, cakes, lip salves and face powder cannot be classed as medicines, and he added that he felt minded to accept the advice of the independent Advisory Committee on Borderline Substances that they have no clinical value, and general practitioners should not be prescribing them. The NHS, he said, "cannot be expected to supply dietary supplements which can be bought over-the-counter in health food shops, and currently cost the NHS over L 60,000 ($91,915) a month."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight